Winton Group’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $270K | Buy |
+1,600
| New | +$237K | 0.01% | 920 |
|
|
2025
Q4 | – | Sell |
-5,360
| Closed | -$752K | – | 1050 |
|
|
2025
Q3 | $752K | Buy |
5,360
+1,957
| +58% | +$265K | 0.03% | 511 |
|
|
2025
Q2 | $428K | Sell |
3,403
-4,254
| -56% | -$488K | 0.02% | 626 |
|
|
2025
Q1 | $847K | Buy |
7,657
+136
| +2% | +$17.2K | 0.05% | 453 |
|
|
2024
Q4 | $1.03M | Buy |
+7,521
| New | +$930K | 0.07% | 352 |
|
|
2024
Q3 | – | Sell |
-10,689
| Closed | -$1.47M | – | 726 |
|
|
2024
Q2 | $1.47M | Buy |
+10,689
| New | +$1.47M | 0.1% | 151 |
|
|
2024
Q1 | – | Sell |
-4,155
| Closed | -$547K | – | 784 |
|
|
2023
Q4 | $547K | Sell |
4,155
-117
| -3% | -$13.5K | 0.04% | 237 |
|
|
2023
Q3 | $481K | Buy |
4,272
+1,738
| +69% | +$183K | 0.04% | 260 |
|
|
2023
Q2 | $239K | Sell |
2,534
-39,708
| -94% | -$3.88M | 0.02% | 610 |
|
|
2023
Q1 | $4.28M | Buy |
42,242
+12,542
| +42% | +$1.31M | 0.26% | 56 |
|
|
2022
Q4 | $3.55M | Sell |
29,700
-16,429
| -36% | -$1.92M | 0.23% | 72 |
|
|
2022
Q3 | $4.9M | Buy |
46,129
+2,849
| +7% | +$289K | 0.32% | 48 |
|
|
2022
Q2 | $4.22M | Buy |
43,280
+6,773
| +19% | +$625K | 0.22% | 92 |
|
|
2022
Q1 | $3.42M | Sell |
36,507
-3,954
| -10% | -$335K | 0.18% | 110 |
|
|
2021
Q4 | $3.45M | Buy |
40,461
+19,957
| +97% | +$1.84M | 0.21% | 86 |
|
|
2021
Q3 | $1.97M | Sell |
20,504
-1,283
| -6% | -$121K | 0.11% | 185 |
|
|
2021
Q2 | $2.12M | Sell |
21,787
-955
| -4% | -$91.5K | 0.11% | 165 |
|
|
2021
Q1 | $2.21M | Buy |
22,742
+1,165
| +5% | +$122K | 0.13% | 119 |
|
|
2020
Q4 | $2.07M | Sell |
21,577
-42,075
| -66% | -$4.06M | 0.15% | 97 |
|
|
2020
Q3 | $6.12M | Buy |
63,652
+8,149
| +15% | +$943K | 0.2% | 82 |
|
|
2020
Q2 | $6.77M | Buy |
55,503
+14,363
| +35% | +$1.59M | 0.17% | 116 |
|
|
2020
Q1 | $3.56M | Buy |
41,140
+7,496
| +22% | +$734K | 0.09% | 378 |
|
|
2019
Q4 | $3.62M | Buy |
33,644
+20,505
| +156% | +$2.15M | 0.05% | 584 |
|
|
2019
Q3 | $1.18M | Buy |
+13,139
| New | +$1.23M | 0.01% | 760 |
|
|
2019
Q2 | – | Sell |
-4,471
| Closed | -$394K | – | 1238 |
|
|
2019
Q1 | $394K | Sell |
4,471
-1,367
| -23% | -$114K | 0.01% | 684 |
|
|
2018
Q4 | $417K | Sell |
5,838
-226
| -4% | -$21.7K | 0.01% | 546 |
|
|
2018
Q3 | $746K | Sell |
6,064
-54
| -0.9% | -$6.13K | 0.02% | 470 |
|
|
2018
Q2 | $601K | Sell |
6,118
-3,358
| -35% | -$301K | 0.02% | 581 |
|
|
2018
Q1 | $786K | Buy |
+9,476
| New | +$800K | 0.02% | 590 |
|
Other funds holding NBIX
Winton Group's NBIX Position: Q2 2026 in Review
Winton Group opened a new position in Neurocrine Biosciences (NBIX) in Q2 2026: 1,600 shares worth $270K. The stake represents 0.01% of the portfolio and ranks #920 among its holdings. This is a return to the name: Winton Group previously reported a position in NBIX as recently as Q3 2025.
Winton Group first reported a position in NBIX in Q1 2018 and has held it in 29 quarters since. The position peaked at $6.77M in Q2 2020. 774 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- Winton Group held 1,600 shares of Neurocrine Biosciences worth $270K as of Q2 2026.
- Neurocrine Biosciences was a new Winton Group position in Q2 2026.
- Neurocrine Biosciences made up 0.01% of Winton Group's portfolio in Q2 2026, its #920 holding.
- Winton Group first reported a position in Neurocrine Biosciences in Q1 2018 and has held it in 29 quarters since.
- Winton Group's Neurocrine Biosciences position peaked at $6.77M in Q2 2020.
- 774 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.